Background:
Introduction
131 Iodine-metaiodobenzylguanidine ( 131 I-mIBG) offers an effectively targeted radionuclide therapy for neuroblastoma and pheochromocytoma in pediatric patients. The high activities (3.7 to 5.5 GBq) are usually administered to the patient. After high dose treatment, the patient becomes a potential radiation hazard and should be stayed in the hospital until radiation exposures decrease to acceptable limit [1] . In Thailand, the radiation safety regulations and release limit are based on the basic safety standard (BSS) recommended by IAEA (International Atomic Energy Agency) which states a guidance level of 30 mCi (1100 MBq) for release patients who treat with 131 I. In practical, the measured dose rate is below 50 µSv per hour at a distance of 1 meter is used to release a treated patient from the hospital [2] . For 131 I-mIBG, the radiation protection principle is similar to high dose 131 I-NaI (sodium iodide) for thyroid diseases. Due to 131 I-mIBG is administered to pediatric patients, then, it is difficult to control the treated patients and radiation protection might be more complicated. In addition, there is no isolated radiation ward specialized for this group of patients at our institute. Accordingly, the treatment is performed in the general pediatric ward with installation of portable lead shields (an equivalent thickness of 1 inch of lead).
Furthermore, limiting the radiation exposure to their family caregiver in 131 I-mIBG in pediatric patients should be concerned [3] . The ICRP (International Commission on Radiation Protection) and HPA (Health Protection Agency) are specified the value in term of dose constraint rather than dose limit. In their recommendations, the dose constrain per episode for caregiver is < 5 mSv [3] [4] [5] . In Thailand, there is no written policy specific for pediatric patient caregiver who looks after high dose radionuclide treatment. Moreover, there are minimal data in the literature published on this topic. This study intends to measure the radiation exposure in the non-lead-lined treatment room and it surrounding areas for 131 ImIBG high dose treatment located inside the general pediatric ward using OSL (optically stimulated luminescence). We also purpose to study the dose that family caregivers would be received when their children were undergone high dose radionuclide therapy.
Methods
Environmental OSL monitoring with aluminum oxide doped with carbon (Al 2 O 3 :C) InLight® nanoDotTM dosimeter (Landauer, Glenwood, IL, USA) were prepared and calibrated by the Thailand Institute of Nuclear Technology (TINT). The ambient dose equivalent at 10 mm depth H*(10) for estimating of the effective dose was measured for 25 points (2 dosimeters each point) including 13 points in the radionuclide treated room, 3 points in the adjacent-room, 7 points in the hallway and 2 points for background (as demonstrated in Figure 1 ) [6] . In addition as 131 I emitted beta particles which are weakly penetrating radiation, the directional dose equivalents for the skin at d = 0.07 mm H'(0.07,Ω) were analyzed in some areas for example caregiver bed and the area behind lead shielding [7, 8] .
The measurements were performed in four pediatric patients (n=4) whom treated with high dose 131 I-mIBG (activity 3700 -5500 MBq). After measurement, all OSLs read out processes were performed at TINT using the InLight® Automatic reader (Landauer, Glenwood, IL, USA). In addition, the personal dose equivalent H p (10) of family caregiver was recorded in the log book following well instructed using the Aloka pocket digital electronic semiconductor dosimeter model PDM-112 (Hitachi-Aloka Medical, Ltd., Tokyo, Japan). The dosimeter was placed on middle of the chest for each caregiver [9] .
All procedures in this study were approved by the local committee on human experimentation in accordance with the ethical standards of the Helsinki Declaration. All patients and their family caregivers signed an informed consent form prior to any measurements. 
Results
The contamination survey was carried out in all areas prior to hospitalize the pediatric patient in order to ensure that there was no radiation contamination in the assigned treatment room. Twenty-five environmental dosimeters were used to perform area monitoring for control effective dose in term of H*(10) and control of skin dose in term of H'(0.07,Ω).
The measurement was carried for 24 hours including the 131 ImIBG administration process in four patients with the treated activity 3700 -5500 MBq. Table 1 shows the range of ambient dose equivalent H*(10) inside treatments room, adjacent room and surrounding areas. The maximum directional dose equivalents were 30.78 ± 5.87 µSv·h -1 at the caregiver bed. The directional dose equivalents outside the lead shield were ranged from 4.22 ± 0.57 to 10.52 ± 4.59 µSv·h -1 . Consequently, the measured personal dose equivalent H p (10) of family caregiver with patient age are summarized in Table 3 .
The personal dose equivalents for caregiver were 7433 and 6760 µSv for infant pediatric patients. Compare to the caregiver exposure for older patients, the personal dose equivalents were 175 and 1632 µSv for children age of 15 and 5 years respectively. 
Discussions
The radionuclide treated patients are the source of radiation exposure and become a potential radiation hazard to other individuals in their vicinity. In this work, we measured the radiation exposures in the non-lead-lined treatment room and surrounding areas using environmental OSL dosimeter. In our previous work, we already reported the radiation exposure from this non-lead-lined treatment room with portable lead shields, those data were collected in adult patient with high dose 131 I-NaI. However, the radiation safety management was more troublesome in pediatric patients [10] . In this work, the ambient dose equivalents were measured and tabulated in Table 1 . From these results, it is important to note that the dose equivalents in almost all areas higher than the dose limits for occupational and also member of the public exposure as recommended by ICRP. The limits are 10 and 0.5 µSv·h -1 for occupational and member of the public, however, these limits are calculated based on 2000 working hours per year [11] . Hence, these derived limits are being unrealistic for this situation as the 2000 working hours per year are overly restrictive for calculation. In reality, the isolation is not continuous for 1 year, however, this study provides important information in order to obtain useful case planning and radiation control of this room. Hence, the stay time should be limited for both occupational workers and member of the public. For the other pediatric patient whom stayed in the adjacent room, the ambient doses at the wall in adjacent room were ranged from 2.08 to 4.48 µSv·h -1 . These values were slightly greater than the public limit. However, when consider the exposure at patient bed and visitor chair which are located at opposite wall, the exposure to other pediatric patient and their relatives should well below the regulatory limit. Our results were similar to study by Chu et al. from Memorial SloanKettering Cancer Centre which studied the feasibility of administering 131 I-mIBG in treatment room without lead-lined [12] . Chu et al. reordered on 16 131 I-mIBG treatments and described that dose rates in two adjacent rooms were ranges (mean ± 1SD) from 4 ± 2 and 4 ± 5 µSv·h -1 . In addition, the doses outside the treatment room were slightly higher than our study (2 -8 µSv h -1 in Chu et al. versus 1.82 -3.85 µSv·h -1 in our study). Based on our results, the ambient and directional dose equivalent in the caregiver chair were exceed the permitted limit. As the patients are allowed to move within the admitted room. In addition to the patient's bed, the caregiver bed would be another relax seating for the patients. Consequently, this was correlated with high personal dose equivalent to family caregivers which listed as 175, 1632, 6760 and 7433 µSv for the patient age of 15, 5, 1 and 1 Year respectively. As recommended by ICRP and HPA, the dose constrain for caregiver is limited to < 5 mSv per episode [3] . The dose received by family caregivers for infant patients were exceeded the limit. As for these infant patients, the patients were just 1 year old, in diapers and necessitating attention than normal. This finding was correlated with work of Markelewicz RJ et al. and Gains JE et al. [1, 3, 13] . The study by Gains JE et al. reported that caregivers for young patients got higher doses than caregivers for older patients on the 10 years study of radiation exposure in radionuclide treatment of pediatric patient without lead-line treatment room. However, only one caregiver (from 50 caregivers) in Gains et al. was exceed the derived caregiver limit. Accordingly from our findings, the local radiation control policies for the caregiver in very young patient should be reconsidered. Optimistically, the use of realtime pocket dosimeter could help the family caregivers to proactively improve their radiation protection.
Conclusion
These radiation monitoring data provided the important information to manage radiation protection and aware of radiation exposure in an adjacent room to minimize the exposure dose for the members of public and medical staffs in the pediatric ward. The radiation exposure to caregivers were associated with the patient age; hence, caregiver exposure for younger pediatric patient tends to receive higher exposure dose as the patient may require more cares and supports.
